# MDM4 overexpression alleviates developmental and hematopoietic defects in Fancg deficient mice

Maeva Loock, Carèle Fédronie, Carine Torset, Lucie Hernandez, Emmanuelle Latour, Samuel Quentin, Nathalie Gachard, Julie Lefrançois, Loïc Maillard, Francina Langa Vives, et al.

► To cite this version:

Maeva Loock, Carèle Fédronie, Carine Torset, Lucie Hernandez, Emmanuelle Latour, et al. MDM4 overexpression alleviates developmental and hematopoietic defects in Fancg deficient mice. Leukemia, 2025, 39 (10), pp.2542-2546. 10.1038/s41375-025-02692-6 . pasteur-05448399

HAL Id: pasteur-05448399

https://pasteur.hal.science/pasteur-05448399v1

Submitted on 8 Jan 2026

**HAL** is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
LETTER

OPEN

ANIMAL MODELS

# MDM4 overexpression alleviates developmental and hematopoietic defects in Fancg deficient mice

Maeva Loock<fnref n="1" />, Carèle Fédronie², Carine Torset², Lucie Hernandez²,³, Emmanuelle Latour⁴, Samuel Quentin²,³, Nathalie Gachard²,⁵, Julie Lefrançois², Loïc Maillard², Francina Langa Vives⁶, Véronique Parietti⁷, Marie-Laure Arcangeli ID⁸, Camille Lobry ID³, Jean Soulier²,³,¹², Olivier Bluteau ID⁹,¹⁰,¹² and Dominique Bluteau ID<fnref n="1" />,¹¹,¹²✉

© The Author(s) 2025

Leukemia (2025) 39:2542–2546; https://doi.org/10.1038/s41375-025-02692-6

**To the Editor:**

Fanconi anemia (FA) is the most common inherited cause of bone marrow failure (BMF). Most FA patients experience hematopoietic stem cell (HSC) attrition and cytopenia during childhood. Along with intrinsic chromosomal instability, these conditions favor clonal evolution and frequently lead to the emergence of myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML) in their teens or early adulthood. To date, 23 Fanconi Anemia (FA) genes have been identified. They encode proteins that cooperate in the FA pathway whose primary function is the repair of DNA interstrand crosslinks (ICLS) [1]. Moreover, FA pathway is also at the crossroads of several biological processes and its impairment results in multiple cellular dysfunctions such as genotoxicity from endogenous ICL agents, aldehydes [2], physiological proliferative stress [3], elevated p53 levels [4], *MYC* oncogene overexpression [5], hypersensitivity to inflammatory cytokines, oxidative stress and a hyperactive TGF beta pathway [6]. These alterations contribute to the loss of hematopoietic stem and progenitor cells (HSPC) that occurs in FA patients. Currently, allogeneic transplantation remains the only curative therapy to restore hematopoiesis and improve patient survival. Recently, we identified a distinct pattern of somatic structural variants and mutations that engage the cells towards MDS and AML in FA. The hallmark of these alterations consists of microhomology-mediated chromosomal rearrangements leading to copy-number alterations. The most characteristic is the chromosome 1q gain, which drives clonal hematopoiesis through the *MDM4* duplication that dampens p53 signaling [7]. Although FA mouse models, including *Fancg*⁻<fnref n="1" />⁻<fnref n="1" /> mice, partially recapitulate human developmental alterations and hematopoietic defects [8–10], further investigations are required to elucidate the mechanisms predisposing hematopoietic FA cells to leukemic transformation. In this study, we have developed a joint molecular and cellular approach to investigate the “pre-leukemic” state in FA. We generated a *Mdm4* transgenic mouse

strain, *Fancg*⁺/⁺Tg(RPL23-203515) (WTTg), by introducing a wide genomic region surrounding *Mdm4* that includes its proximal regulatory sequences, using a bacterial artificial chromosome (BAC; RPL23-203E15) which resulted in the *Mdm4* overexpression (Supplementary Fig. S1A) [7]. Therefore, we crossed *Fancg*⁺/⁻ and *Fancg*⁺/⁻Tg(RPL23-203515) mice (Supplementary Fig. S1B) to obtain *Fancg*⁻/⁻ (KO). *Fancg*⁻/⁻Tg(RPL23-203515) (KOTg), *Fancg*⁺/⁺Tg(RPL23-203515) (WTTg) and *Fancg*⁺/⁺ (WT) progeny. To verify the stability of *Mdm4* expression over time, we measured *Mdm4* RNA expression levels in the progeny of KOTg and WTTg. As evidenced in Supplementary Fig. S1, *Mdm4* overexpression remain stable in several lineages including PBMC (Supplementary Fig. S1C), Lin⁻ SCA1⁺ KIT⁺ (LSK) and progenitor cells (Supplementary Fig. S1D).

We assessed the consequences of alteration of the FA pathway in HSPCs in KO or in KOTg mice at steady state and under Poly-IC (pIC) induced stress.

As previously reported [11], *Fancg*⁻<fnref n="1" />⁻<fnref n="1" /> mice exhibited perinatal death (Fig. 1A), growth retardation (Supplementary Fig. S2A) and developmental defects of the skull and the eyes (Fig. 1B, Supplementary Fig. S2B). We also observed a decrease of in vitro hematopoietic clonogenic capacity (Fig. 1C), an increased sensitivity to mitomycin C (MMC) (Fig. 1D) and a defect in engraftment capacity in comparison to WT cells (Fig. 1E). Interestingly, constitutive *Mdm4* overexpression in KOTg mice rescued the survival, reduced developmental phenotypes and alleviated hematopoietic defects observed in KO mice (Fig. 1A–F). However, after over 300 days of follow-up neither WTTg nor KOTg mice developed tumor transformation. This result confirms that as in human FA, *Mdm4* overexpression alone is not sufficient to induce cellular transformation.

To finely depict the consequences of *Mdm4* overexpression in the hematopoietic compartment and to understand the setup of the pre leukemic state, we performed RNA-seq analysis on highly

<figure><img src="image_2.png" /></figure>

Check for updates

<footnote n="1">¹CNRS UMR9019, Paris Saclay University, Gustave Roussy Cancer Campus, Villejuif, France. ²Université Paris Cité, Institut de Recherche Saint-Louis (IRSL), INSERM UMR1342/CNRS EMR8000, Paris, France. ³Hematology Laboratory, Hopital Saint-Louis, APHP, Paris, France. ⁴INSERM U1342, Institut de la Leucémie Paris Saint-Louis, Université Paris-Cité, Paris, France. ⁵Hematology laboratory, CHU Limoges, Limoges, France. ⁶Mouse Genetics Engineering Center, Pasteur Institute, Paris, France. ⁷UMS Saint-Louis (US53/UAR2030), University Paris Cité, INSERM, CNRS, Paris, France. ⁸INSERM U1170, Paris Saclay University, Gustave Roussy cancer campus, Villejuif, France. ⁹INSERM UMRS 1166 - ICAN, Faculty of Medicine Pitié-Salpétrière, Sorbonne University, Paris, France. ¹⁰Service de Biochimie Endocrinienne et Oncologique, Assistance publique - Hôpitaux de Paris Sorbonne Université Pitié-Salpétrière, Paris, France. ¹¹EPHE, PSL University, Paris, France. ¹²These authors contributed equally: Jean Soulier, Olivier Bluteau, Dominique Bluteau.</footnote>

<footnote>✉email: dominique.bluteau@ephe.psl.eu</footnote>
<figure><img src="image_3.png" /><figcaption>**Fig. 1** *Mdm4* overexpression partially rescued developmental and hematopoietic defects of KO mice. A Survival of KO mice compared to WT and KOTg mice. *P* = 0.007 for KO compared with WT by the log-rank test for trend. B Representative image of 2 months old WT, WTTg, KO and KOTg mice. C Percent of CFU-C compared to WT. Colonies (primary CFU-C) of 3000 BM Lin⁻ cells were quantified after 7 days in methylcellulose (P1) (*n* = 6); Cells recovered from primary CFU-C plates were seeded in new CFU-C medium to perform serial CFU-C assay. Total cells (1%) of equivalent primary plates were seeded in triplicate. Secondary CFU-C was quantified 7 days later (P2), (*n* = 4); D Impaired clonogenic capacity of WT (*n* = 4), KOTg (*n* = 5) and KO (*n* = 5) cells over 10-day treatment with MMC. Data represent mean ± SEM of independent experiments each of which was plated in triplicate cultures isolated from the BM of 8–12 weeks-old syngeneic mice, multiple unpaired t-test was used to determine *p*-values. E Percent of CD45.2 cells in recipient mice, 16 weeks after transplant. Experimental design: WT, KO, KOTg or WTTg BMCs (CD45.2) and isogenic WT (CD45.1) cells were co-transplanted into lethally irradiated recipient mice (45.1). Each symbol represents an individual recipient animal; large horizontal bars represent the mean of each group. Error bars represent mean ± SEM, two-ways ANOVA was used to determine *p* values.</figcaption></figure>

purified LSK cells from KO, WT and KOTg individual mice at steady state and 48 h post pIC stress (5 mg/Kg). At steady state, only a limited number of differentially expressed genes were detected in KO LSK cells compared to WT cells, suggesting that only subtle perturbations are tolerable for LSK cells with *Fancg* deletion to survive. Surprisingly, no major transcriptomic differences were observed in KO LSK cells post pIC compared to WT. However, pathway enrichment analysis highlighted significant similarities between KO LSK and WT LSK post pIC stress (Fig. 2A). Using GSEA analysis and in accordance with data obtained in FA patient cells [5], we confirmed that the expression of several key genes involved in HSC stemness was perturbed in KO LSK subsets with an enrichment of TP53 and MYC pathways compared to WT (Fig. 2A, Supplementary Fig. S3A). Notably, except for cell cycle pathway signature, all these enrichment profiles were reverted upon Mdm4 overexpression in LSK KO cells (Fig. 2A, Supplementary Fig. S3A).

Alongside this LSK transcriptomic analysis, we performed an exhaustive cellular study including quantification of apoptosis and cell cycle analysis, with or without stress (Fig. 2B–F). Interestingly, KO mice displayed a reduced LSK population in bone marrow (BM) at steady state and post pIC stress (Fig. 2B), a cell cycle alteration characterized by G1 phase blockade (Fig. 2C) and an increase in apoptosis (Fig. 2D) in comparison to WT cells. The overexpression of Mdm4 rescued the response of KO LSK cells to pIC inflammatory stress, with a number of KOTg LSK cells comparable to the one of WT LSK. However, this overexpression was not sufficient to rescue the number of KO LSK cells in steady state BM (Fig. 2B). The LSK compartment is enriched in HSPC-population but can be further divided into long-term hematopoietic stem cells (LT-HSC), short-term HSC (ST-HSC) or multipotent progenitors (MPP) 2, MPP3 and MPP4 [12] (gating strategy Supplementary Fig. S3B). We showed that WT LSK populations exhibit an inflammatory cellular response post pIC characterized by an increased number of total LSK (Fig. 2B)
A

<figure><img src="image_4.png" /></figure>

C

<figure><img src="image_5.png" /></figure>

E

<figure><img src="image_6.png" /></figure>

F

<figure><img src="image_7.png" /></figure>

B

<figure><img src="image_8.png" /></figure>

D

<figure><img src="image_9.png" /></figure>

**Fig. 2 Mdm4 overexpression decreases apoptosis and restores cells number and inflammatory response under stress of KO LSK cells.**

**A** GSEA analysis representation from LSK cells, RNAseq analysis. **B** Total number of BM cells in 8–12-weeks old WT (n = 4), WT_plc (n = 3), KOTg (n = 5), KOTg_plc (n = 3), KO (n = 3) and KO_plc (n = 4) mice (mean ± SEM). **C** Cell cycle analysis of LSK cells in 8-12-weeks old WT (n = 4), WT_plc (n = 3), KOTg (n = 3), KOTg_plc (n = 3), KO (n = 4) and KO_plc (n = 4) mice. Error bars represent mean ± SEM, two-ways ANOVA was used to determine p values (*p* < 0.05). **D** Apoptosis analysis of LSK cells in 8–12-weeks old WT (n = 9), WT_plc (n = 8), KOTg (n = 7), KOTg_plc (n = 3), KO (n = 7) and KO_plc (n = 5) mice. Error bars represent mean ± SEM, two-ways ANOVA was used to determine p values (*p* < 0.05). **E** Total number of BM LT-HSC (Lin−Sca-1+c-Kit+CD48−CD150+), ST-HSC (c-Kit+Lin−Sca-1+ CD135− CD34+), or F multipotent progenitor (MPP2, Lin−Sca-1+c-Kit+ CD135- CD48+ CD150+), (MPP3, Lin−Sca-1+c-Kit+ CD135- CD48+ CD150-), (MPP4, Lin−Sca-1+c-Kit+ CD135+). Error bars represent mean ± SEM, two-ways ANOVA was used to determine p values (*p* 0.05).
corresponding to an increased number of cells in MPP2, 3 and 4 compartments (Fig. 2E, F). In post-inflammatory stress, we did not observe a significant increase of KO LSK cells (Fig. 2B), but on contrary a huge increase of cell apoptosis (Fig. 2D) and an attenuated inflammatory cellular response in all LSK subsets (Fig. 2E, F). In addition, the strong increase in apoptosis KO LSK cells (Fig. 2D) was restricted to the MPP3, MPP4 and ST-HSC populations (Supplementary Fig. S3C, D). These results could explain the origin of BM failure observed in FA patients; this could be due to the increase in apoptosis of multipotent progenitor's cells. The specific effect of *Mdm4* overexpression is the decrease of LSK apoptosis (especially in ST-HSC, MPP3 and MPP4 compartment, Fig. 2B; Supplementary Figs. S4A, S5A) but, in accordance with RNA-seq data, is not sufficient to rescue cell cycle arrest in G1 phase compared to KO mice (Fig. 2C; Supplementary Figs. S4B, S5B). Additionally, we assessed γH2AX and 53BP1 foci in HSPCs cultured in vitro, with or without MMC, using cells derived from WT, KO and KOTg mice (Supplementary Fig. S5C, D). Altogether, these results suggest that KOTg cells are able to survive by tolerating damaged DNA.

In conclusion, we developed an original transgenic mouse model able to determine the impact of *Mdm4* overexpression in the rescue of FA developmental, cellular, and molecular phenotype that are observed in human. This model is designed to allow the innate regulation of *Mdm4* since we included its natural promoter and proximal regulating sequences. Crossing with *Fancg*⁻/⁻ mice model rescued FA developmental defects but also alleviate cellular and molecular phenotypes observed in these mice. We have clearly shown that overexpression of *Mdm4* inhibits apoptosis in HSPC FA cells under stress, enabling them to survive. However, the blockade of cell cycle observed in KO cells is not rescued by *Mdm4* overexpression, suggesting the involvement of other mechanisms. Unlike FA mouse models crossed with *Trp53* knockout mice [13, 14], KOTg mice do not spontaneously develop tumor transformation over time. *TP53* deletion is one of the most common genomic events observed in squamous cell carcinomas from FA patients [15]. However, *TP53* inactivation is not a common mechanism of FA leukemogenesis. Accordingly with our hypothesis and the natural history of oncogenesis in FA, our model accurately recapitulates features of human FA hematopoietic disease evolution with an attenuation of p53 dependent apoptosis allowing cell survival. This confirms that a complete leukemic transformation will depend on additional genomic events. Therefore, this new model could be considered as a preleukemic/pre-oncogenic model that is relevant in context of FA patient's genomic alterations previously described. The pre-leukemic state in FA requires additional events to facilitate cellular transformation. Indeed, in RNA-Seq analysis, we also have identified other deregulated genes that were not been previously highlighted but that are functionally highly relevant in FA disease. In particular, we identified several genes whose expression is altered in murine FA-deficient hematopoietic cells, supporting the exacerbation of the TP53 pathway alongside the additional chromosome alterations that occur during the leukemic evolution of FA. In this context, the challenge is now to precisely determine how these targets would be involved in leukemic progression, whether they can be used as new markers of FA disease progression as well as prognostic markers of transformation in patients.

## REFERENCES

1. Ceccaldi R, Sarangi P, D'Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17:337-49.

2. Garaycochea JI, Crossan GP, Langevin F, Mulderrig L, Louzada S, Yang F, et al. Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells. Nature. 2018;553:171-7.

3. Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature. 2015;520:549-52.

4. Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11:36-49.

5. Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, et al. MYC promotes bone marrow stem cell dysfunction in Fanconi anemia. Cell Stem Cell. 2021;28:33-47.e8.

6. Zhang H, Kozono DE, O'Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton A, et al. TGF-beta inhibition rescues hematopoietic stem cell defects and bone marrow failure in Fanconi anemia. Cell Stem Cell. 2016;18:668-81.

7. Sebert M, Gachet S, Leblanc T, Rousseau A, Bluteau O, Kim R, et al. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. Cell Stem Cell. 2023;30:153-70 e9.

8. Barroca V, Mouthon MA, Lewandowski D, Brunet de la Grange P, Gauthier LR, Pflumio F, et al. Impaired functionality and homing of Fancg-deficient hematopoietic stem cells. Hum Mol Genet. 2012;21:121-35.

9. Mazon M, Julien J, Ung RV, Picard S, Hamoudi D, Tam R, et al. Deletion of the Fanconi anemia c gene in mice leads to skeletal anomalies and defective bone mineralization and microarchitecture. J Bone Min Res. 2018;33:2007-20.

10. Parmar K, D'Andrea A, Niedernhofer LJ. Mouse models of Fanconi anemia. Mutation Res. 2009;668:133-40.

11. Domenech C, Maillard L, Rousseau A, Guidez F, Petit L, Pla M, et al. Studies in an early development window unveils a severe HSC defect in both murine and human Fanconi anemia. Stem Cell Rep. 2018;11:1075-91.

12. Pietras EM, Reynaud D, Kang YA, Carlin D, Calero-Nieto FJ, Leavitt AD, et al. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell. 2015;17:35-46.

13. Freie B, Li X, Ciccone SL, Nawa K, Cooper S, Vogelweid C, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood. 2003;102: 4146-52.

14. Houghtaling S, Granville L, Akkari Y, Torimaru Y, Olson S, Finegold M, et al. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res. 2005;65:85-91.

15. Webster ALH, Sanders MA, Patel K, Dietrich R, Noonan RJ, Lach FP, et al. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. Nature. 2022;612:495-502.

## ACKNOWLEDGEMENTS

We thank the CIGM team (Mouse Genetics Engineering Center, Pasteur Institute) for technical support in microinjection experiments and animal husbandry. M.L was a PhD fellow of ministère de la recherche et de l'enseignement et supported by Société Française d'Hématologie.

## AUTHOR CONTRIBUTIONS

Conceptualization of the project: BD, BO, SJ; Data collection and analysis: BD, BO, LM, FC, LE, QS; Contribution of data/samples: TC, HL, GN, PV, LVF, JG, ML; Discussion and interpretation of results: BD, BO, SJ, AML, LC; Drafting of manuscript: BD, BO, AML; All authors reviewed the final manuscript.

## FUNDING

This work is supported by the Association Française pour la Maladie de Fanconi (AFMF) (grant 'Modélisation de la transformation leucémique dans la maladie de Fanconi'), La Ligue régionale contre le cancer (comité94), Fondation ARC (ARCPJA2021050003623), l'association Aremig (Société Française de Recherche contre le Cancer de l'Enfant) to D.B. The European Research Council (ERC) Grant to J.S. (CEVAL-311660). The Institut de Recherche Saint-Louis (IRSL, Université Paris Cité) animal facility is supported by the IHUB program THEMA, the Paris Comprehensive Leukemia Institute (Agence National de la Recherche). Fondation ARC, INCA PLBIO program (PLBIO23-246 to MLA and PLBIO20-246 and PLBIO20-074, to C.L.) and SiRIC InsiTu (INCA-DGOSINSERM-ITMO Cancer_18008, to C.L.). Open access funding provided by Université Paris-Saclay.

## COMPETING INTERESTS

The authors declare no competing interests.
ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41375-025-02692-6.

**Correspondence** and requests for materials should be addressed to
Dominique Bluteau.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_10.png" /></figure>

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2025